HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) All Versions of this Article: CJN.01260209v1 4/7/1222    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Google Scholar Articles by Brown, M. C. PubMed PubMed Citation Articles by Brown, M. C.

Encapsulating Peritoneal Sclerosis in the New Millennium: A National Cohort Study

Michaela C. Brown^*, Keith Simpson^*, Jan J. Kerssens, Robert A. Mactier^*; on behalf of the Scottish Renal Registry

^* Scottish Renal Registry, Royal Infirmary, Glasgow, United Kingdom; Information Services Division (ISD), Edinburgh, United Kingdom

Correspondence: Dr. Michaela C. Brown, Scottish Renal Registry, 3^rd Floor Walton Building, Glasgow Royal Infirmary, Castle Street, Glasgow G4 0SF, UK. Phone: +44 141 211 5171; Fax: +44 141 211 4843; E-mail: michaelacbrown{at}hotmail.com

Background and objectives: The study aim was to establish the incidence and characterize all encapsulating peritoneal sclerosis (EPS) cases in patients treated by peritoneal dialysis (PD).

Design, setting, participants, & measurements: The patient cohort, which started PD from January 1, 2000, to December 31, 2007, was identified from the Scottish Renal Registry (n = 1238). Possible EPS cases were identified by the ten adult Scottish renal units. Patient records were examined to ensure cases met diagnostic criteria.

Results: Forty-six cases were identified; 19 had their first PD exposure after January 1, 2000. The rate was 1.5%, an incidence of 4.9 per 1000 person-years. The incidence increased with PD duration, with rates of 0, 0.6, 2.0, 3.5, 8.1, 8.8 and 5% at <1, 1 to 2, >2 to 3, >3 to 4, >4 to 5, >5 to 6 and >6 yr PD exposure, respectively. The median PD duration of EPS cases was 5.1 yr (interquartile range [IQR] 3.4 to 6.1 yr). At diagnosis, 12 (26%) were on PD and 33 (72%) were diagnosed <2 yr after PD stopped. The cases had a median of 3.3 episodes of peritonitis (range 0 to 20, IQR 1 to 4.5). Thirty (65%) had used 3.86% dextrose dialysate and 45 (98%) had used Extraneal. The mortality was 42% at 1 yr postdiagnosis with a median survival of 149 d (IQR 61 to 408 d).

Conclusions: The incidence reported in this study may be used to inform patients of the minimum risk of developing EPS on PD.

This article has been cited by other articles:

				E. A. Brown, W. Van Biesen, F. O. Finkelstein, H. Hurst, D. W. Johnson, H. Kawanishi, R. Pecoits-Filho, G. Woodrow, and the ISPD Working Party LENGTH OF TIME ON PERITONEAL DIALYSIS AND ENCAPSULATING PERITONEAL SCLEROSIS: POSITION PAPER FOR ISPD Perit. Dial. Int., November 1, 2009; 29(6): 595 - 600. [Full Text] [PDF]